Searched for
BROWNFIELD PHARMACEUTICALS
Buy, Sell or Hold: Citi maintains buy on Eicher Motors; Goldman Sachs retains buy on Max HealthcareBrokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...- Cabot Sanmar announces Rs 220 crore expansion of manufacturing capacity for fumed silicaCabot Sanmar announced the expansion of their fumed silica manufacturing capacity with an investment of Rs 220 crore ($25 million) to meet ...
- Mega FDI plan to focus on faster pharma approvalsThe govt has begun examining ways to shore up foreign investments, including a fast-track mechanism to clear applications of companies espe...
- FDI regime yet to take off pending the changes in foreign exchange lawsInvestors will have to either approach the foreign investment promotion board (FIPB) for approvals or wait till the changes are notified.
- Pharma sector receives Rs 4,975-crore FDI in FY16: GovernmentFDI policy provides for 100 per cent FDI under automatic route in greenfield pharma and upto 100 per cent under government route in brownfi...
- Pharma sector to grow by 20 per cent on relaxed FDI norms: Ananth Kumar"The pharma industry is growing by 14 per cent every year. With relaxed FDI norms, I think pharma sector will grow by 20 per cent," Kumar s...
- FDI up to 74% in brownfield pharma under automatic routeThe government today allowed up to 74 per cent foreign direct investment in the existing pharmaceutical companies through automatic route.
- Government weighs relaxing FDI norms in brownfield pharma companiesAccording to a proposal, FDI up to 49% should be allowed through the automatic route and anything beyond through approval of the FIPB, sour...
- Government to conduct study to assess impact of FDI in pharma industryThe experts would look into the impact of foreign direct investment in the brownfield pharmaceutical companies and access to affordable med...
- Finance Ministry pitches for easing of FDI norms in pharma sectorIndia is now keen on drawing investments into the pharmaceuticals segment to reduce dependence on China for bulk drugs.
- The full spectrum on FDI in brownfield companiesWe must first assess the need of the pharma sector and then evaluate whether mere change of ownership would meet its needs.
- Union Cabinet rejects DIPP proposal to limit FDI in pharmaThe Union Cabinet has rejected a proposal to limit foreign direct investment in domestic manufacturers of “rare and critical” drugs.
- Government not to reduce FDI cap in existing pharma companiesCurrently, 100 per cent FDI is permitted in brownfield pharma firms through clearance from the Foreign Investment Promotion Board (FIPB).
- Arun Maira critical of FIPB, says CCI a better betArun Maira launched a broadside against the FIPB, criticising the process by which it approves overseas investment proposals as being opaqu...
- Govt to soon finalise FDI policy on pharma sectorChidambaram today said the government will soon finalise the foreign investment policy on brownfield pharmaceutical projects.
- Medical devices may skip stiff FDI norms, Government plans to create sub category within pharma sectorDIPP will soon move a note in consultation with the health ministry, department of pharmaceuticals and the finance ministry creating a new ...
- Anand Sharma wants Prime Minister to convene meet to review FDI policy in pharmaCommerce Minister Anand Sharma has urged Prime Minister Manmohan Singh to convene a high-level review meeting to deliberate on the matter.
- Eight FDI proposals in pharma for Rs 1,842.55 cr approved: Srikant Kumar JenaGovt said a total of eight proposals amounting to Rs 1,842.55 cr relating to FDI in brownfield pharma sector were approved in August this y...
- DIPP to take call on allowing 49 per cent FDI in pharmaceutical firmsDIPP may consider allowing foreign direct investment of up to 49 per cent through automatic route in existing Indian pharmaceutical firms.
- Government to ensure Indian pharma firms to make, sell drugs after being acquired by a foreign firmAn inter-ministerial group set up by the finance ministry to consider new norms for clearing FDI proposals in pharmaceutical sector.
Load More
